The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer

被引：1

作者：

Hu, Zongfeng ^{[1
]}

Liu, Wenqi ^{[1
]}

Liu, Jiajia ^{[2
]}

Zhou, Hua ^{[2
]}

Sun, Chunyang ^{[2
]}

Tian, Chao ^{[2
]}

Guo, Xiaona ^{[1
]}

Zhu, Chengyang ^{[1
]}

Shao, Mingxia ^{[1
]}

Wang, Shengrun ^{[1
]}

Wei, Lijun ^{[1
]}

Liu, Min ^{[1
]}

Li, Shuzhen ^{[1
]}

Wang, Jinyu ^{[1
]}

Xu, Haitian ^{[1
]}

Zhu, Wei ^{[1
]}

Li, Xiaopeng ^{[1
,2
]}

Li, Jingfeng ^{[1
]}

机构：

[1] Yantai Univ, Sch Pharm, Yantai 264005, Shandong, Peoples R China

[2] Beijing WellGene Co Ltd, Beijing 100085, Peoples R China

来源：

ANTIVIRAL RESEARCH | 2024年 / 232卷

基金：

中国国家自然科学基金;

关键词：

Oncolytic virus; HSV-1; CRISPR/Cas9; HPV16; Cervical cancer; IN-VIVO; CELLS; REPLICATION; CISPLATIN; THERAPY; GENOME; E6;

D O I：

10.1016/j.antiviral.2024.106035

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cervical cancer, often driven by high-risk human papillomavirus (HPV) infections such as HPV16 or HPV18, remains a leading cause of cancer-related deaths. HPV16, found in about 90% of cervical cancer patients, harbors key oncogenic related genes (E6, E7, E2, E5) and an upstream regulatory region (URR) that contribute to cancer progression. This study introduces a novel approach using a recombinant oncolytic herpes simplex virus type 1 (HSV-1) named SONC103, armed with a CRISPR/Cas9 gene editing system. The aim was to target and disrupt integrated HPV16 genes in cervical cancer cells. Results demonstrated SONC103's capability to specifically and effectively knock down HPV16 oncogenes, thereby reducing cell proliferation and promoting apoptosis. Analyses further revealed loss of HPV16 DNA probes in infected cells' chromosomes, significant regulation of cellular processes related to tumor apoptosis, and downregulation of E6/E7 oncoproteins while increasing tumor suppressor proteins P53 and pRB. Notably, SONC103 exhibited substantial inhibition of tumor growth in a murine xenograft cervical cancer model. This study showcases the potential of the recombinant oncolytic HSV-1 virus (SONC103) in combating HPV16-positive cervical cancer by targeting oncogenes and facilitating oncolysis.

引用

页数：10

共 36 条

[21] T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways [J].

Liu, Haixia ;

Song, Mei ;

Sun, Xiaoyan ;

Zhang, Xin ;

Miao, Huayan ;

Wang, Yankui .

BIOENGINEERED, 2021, 12 (01) :565-577

[22] Antiproliferative effects of AAV-delivered CRISPR/Cas9-based degradation of the HPV18-E6 gene in HeLa cells [J].

Noroozi, Zahra ;

Shamsara, Mehdi ;

Valipour, Elahe ;

Esfandyari, Sahar ;

Ehghaghi, Alireza ;

Monfaredan, Amir ;

Azizi, Zahra ;

Motevaseli, Elahe ;

Modarressi, Mohammad Hossein .

SCIENTIFIC REPORTS, 2022, 12 (01)

[23] Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy [J].

Rasul, Mohammed Fatih ;

Hussen, Bashdar Mahmud ;

Salihi, Abbas ;

Ismael, Bnar Saleh ;

Jalal, Paywast Jamal ;

Zanichelli, Anna ;

Jamali, Elena ;

Baniahmad, Aria ;

Ghafouri-Fard, Soudeh ;

Basiri, Abbas ;

Taheri, Mohammad .

MOLECULAR CANCER, 2022, 21 (01)

[24] PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance [J].

Russell, Luke ;

Swanner, Jessica ;

Jaime-Ramirez, Alena Cristina ;

Wang, Yufeng ;

Sprague, Alex ;

Banasavadi-Siddegowda, Yeshavanth ;

Yoo, Ji Young ;

Sizemore, Gina M. ;

Kladney, Raleigh ;

Zhang, Jianying ;

Lehman, Norman L. ;

Ostrowski, Michael C. ;

Hong, Bangxing ;

Caligiuri, Michael ;

Yu, Jianhua ;

Kaur, Balveen .

NATURE COMMUNICATIONS, 2018, 9

[25] Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system [J].

Sakuma, Tetsushi ;

Nishikawa, Ayami ;

Kume, Satoshi ;

Chayama, Kazuaki ;

Yamamoto, Takashi .

SCIENTIFIC REPORTS, 2014, 4

[26] Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7 [J].

Sato, Naoto ;

Saga, Yasushi ;

Uchibori, Ryosuke ;

Tsukahara, Tomonori ;

Urabe, Masashi ;

Kume, Akihiro ;

Fujiwara, Hiroyuki ;

Suzuki, Mitsuaki ;

Ozawa, Keiya ;

Mizukami, Hiroaki .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (03) :687-696

[27] Therapy with oncolytic viruses: progress and challenges [J].

Shalhout, Sophia Z. ;

Miller, David M. ;

Emerick, Kevin S. ;

Kaufman, Howard L. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (03) :160-177

[28] RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53 [J].

Sima, Ni ;

Wang, Wei ;

Kong, Debo ;

Deng, Dongrui ;

Xu, Qian ;

Zhou, Jianfeng ;

Xu, Gang ;

Meng, Li ;

Lu, Yunping ;

Wang, Shixuan ;

Ma, Ding .

APOPTOSIS, 2008, 13 (02) :273-281

[29] Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody [J].

Tian, Chao ;

Liu, Jiajia ;

Zhou, Hua ;

Li, Jingfeng ;

Sun, Chunyang ;

Zhu, Wei ;

Yin, Yuxin ;

Li, Xiaopeng .

CANCER LETTERS, 2021, 518 :49-58

[30] Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6/E7 genes in cervical cancer cells [J].

Tian, Rui ;

Liu, Jiashuo ;

Fan, Weiwen ;

Li, Rui ;

Cui, Zifeng ;

Jin, Zhuang ;

Huang, Zhaoyue ;

Xie, Hongxian ;

Li, Lifang ;

Huang, Zheying ;

Hu, Zheng ;

Zhou, Ping ;

Tian, Xun .

MOLECULAR THERAPY ONCOLYTICS, 2022, 24 :171-179

← 1 2 3 4 →